- Home
- ENTX vs EDF Comparison
ENTX vs EDF Comparison
Compare ENTX & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- EDF
- Stock Information
- Founded
- ENTX 2010
- EDF 2010
- Country
- ENTX Israel
- EDF United States
- Employees
- ENTX N/A
- EDF N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- EDF Investment Managers
- Sector
- ENTX Health Care
- EDF Finance
- Exchange
- ENTX Nasdaq
- EDF Nasdaq
- Market Cap
- ENTX 142.0M
- EDF 160.2M
- IPO Year
- ENTX 2018
- EDF N/A
- Fundamental
- Price
- ENTX $3.14
- EDF $4.92
- Analyst Decision
- ENTX Strong Buy
- EDF
- Analyst Count
- ENTX 1
- EDF 0
- Target Price
- ENTX $10.00
- EDF N/A
- AVG Volume (30 Days)
- ENTX 283.9K
- EDF 160.6K
- Earning Date
- ENTX 11-07-2025
- EDF 01-01-0001
- Dividend Yield
- ENTX N/A
- EDF 13.14%
- EPS Growth
- ENTX N/A
- EDF N/A
- EPS
- ENTX N/A
- EDF N/A
- Revenue
- ENTX $166,000.00
- EDF N/A
- Revenue This Year
- ENTX N/A
- EDF N/A
- Revenue Next Year
- ENTX N/A
- EDF N/A
- P/E Ratio
- ENTX N/A
- EDF N/A
- Revenue Growth
- ENTX 191.23
- EDF N/A
- 52 Week Low
- ENTX $1.50
- EDF $3.51
- 52 Week High
- ENTX $3.22
- EDF $5.50
- Technical
- Relative Strength Index (RSI)
- ENTX 71.14
- EDF 42.16
- Support Level
- ENTX $2.45
- EDF $4.93
- Resistance Level
- ENTX $3.22
- EDF $5.00
- Average True Range (ATR)
- ENTX 0.23
- EDF 0.06
- MACD
- ENTX 0.05
- EDF 0.00
- Stochastic Oscillator
- ENTX 89.09
- EDF 40.00
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.